Interestingly, in breast cancer, it has been shown that CD44 was associated with longer disease-free-survival (DFS) in estrogen-receptor (ER) positive women, while CD44 positive tumors were associated with poor outcome in ER-negative patients (169). Here, ESR1 is linked to breast carcinoma.